Clinical Efficacy of Immunotherapy with Pd-1/Pd-L1 Inhibitors for the Treatment of Advanced Non-Small Cell Lung Cancer
Download as PDF
Shengjie Yang, Xiao MA, Wenjie Zhang, Qing CHEN, Qisen Guo
Immunotherapeutics like programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors effectively control non-small cell lung cancer (NSCLC) in clinical trials. This study assessed the association of different clinicopathological parameters with the treatment effectiveness and prognosis of NSCLC patients in a real-world setting. Seventy-five patients received PD-1/PD-L1 inhibitors and were evaluated for overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Eighteen patients reached a partial response (PR) (24%), 45 had stable disease (SD) (60%), and 12 had progressive disease (PD) (16%), resulting in an ORR of 24% and a DCR of 84%. For the 11 PD-L1-positive patients, the ORR was 36.36%. Moreover, 16 patients (21%) had died and 34 (45%) had SD at the last follow-up, leading to a PFS of 8.3 months (95% confidence interval (CI): 6.8–12.2 months) and an OS of 17 months (95%CI: 16.7–26.5 months). The Eastern Cooperative Oncology Group (ECOG) score was associated with the treatment-related PFS and OS. The factors associated with the prognosis were ECOG score, line of immunotherapy, tobacco smoking, PD-L1 positivity, and tumor pathology. This study confirmed the clinical effectiveness of PD-1/PD-L1 inhibitor immunotherapy against advanced NSCLC.
Lung cancer; Pd-1; Pd-l1; Pd-1/pd-l1 inhibitors; Effectiveness; Survival